Baseline clinical and pathological characteristics of patients with PPD compared with all patients without PPD in the LEO cohort
| Variable . | PPD (N =145) . | All non-PPD (N = 2610) . | Total (N = 2755) . | P value . |
|---|---|---|---|---|
| n (%) . | n (%) . | n (%) . | ||
| Age at diagnosis, y | .610∗ | |||
| Median (range) | 62.5 (19-88) | 63.0 (18-99) | 63.0 (18-99) | |
| Sex | .026† | |||
| F | 50 (34.7%) | 1153 (44.2%) | 1203 (43.7%) | |
| M | 94 (65.3%) | 1456 (55.8%) | 1550 (56.3%) | |
| Race | .892† | |||
| White | 127 (88.2%) | 2217 (85.0%) | 2344 (85.1%) | |
| Black or African American | 10 (6.9%) | 192 (7.4%) | 202 (7.3%) | |
| Unknown/not reported | 4 (2.8%) | 101 (3.9%) | 105 (3.8%) | |
| Asian | 3 (2.1%) | 74 (2.8%) | 77 (2.8%) | |
| >1 race | 0 (0.0%) | 17 (0.7%) | 17 (0.6%) | |
| American Indian/Alaska Native | 0 (0.0%) | 4 (0.2%) | 4 (0.1%) | |
| Native Hawaiian/Pacific Islander | 0 (0.0%) | 4 (0.2%) | 4 (0.1%) | |
| Ethnicity | .764† | |||
| Hispanic/Latinx | 15 (10.4%) | 325 (12.5%) | 340 (12.4%) | |
| Not Hispanic or Latinx | 126 (87.5%) | 2227 (85.4%) | 2353 (85.5%) | |
| Unknown/Not reported | 3 (2.1%) | 57 (2.2%) | 60 (2.2%) | |
| Diagnosis time interval (days) | <.001† | |||
| ≤ 14 | 68 (49.6%) | 755 (30.4%) | 823 (31.4%) | |
| > 14 | 69 (50.4%) | 1731 (69.6%) | 1800 (68.6%) | |
| Missing | 8 | 124 | 132 | |
| ECOG PS | .053† | |||
| <2 | 104 (77.0%) | 2040 (83.4%) | 2144 (83.1%) | |
| ≥2 | 31 (23.0%) | 405 (16.6%) | 436 (16.9%) | |
| Missing | 10 | 165 | 175 | |
| LDH | <.001† | |||
| ≤Normal | 27 (23.7%) | 1038 (45.2%) | 1065 (44.2%) | |
| >Normal | 87 (76.3%) | 1256 (54.8%) | 1343 (55.8%) | |
| Missing | 31 | 316 | 347 | |
| Extranodal sites | .009† | |||
| ≤1 | 92 (64.8%) | 1905 (74.7%) | 1997 (74.2%) | |
| >1 | 50 (35.2%) | 646 (25.3%) | 696 (25.8%) | |
| Missing | 3 | 59 | 62 | |
| Ann Arbor stage | <.001† | |||
| I-II | 26 (19.5%) | 950 (38.5%) | 976 (37.5%) | |
| III-IV | 107 (80.5%) | 1520 (61.5%) | 1627 (62.5%) | |
| Missing | 12 | 140 | 152 | |
| IPI group | .003† | |||
| 0-1, low | 37 (25.7%) | 956 (36.6%) | 993 (36.1%) | |
| 2, low intermediate | 35 (24.3%) | 735 (28.2%) | 770 (28.0%) | |
| 3, high intermediate | 42 (29.2%) | 574 (22.0%) | 616 (22.4%) | |
| 4-5, high | 30 (20.8%) | 344 (13.2%) | 374 (13.6%) | |
| Missing | 1 | 1 | 2 | |
| Cell of origin | .285† | |||
| Known GCB | 45 (58.4%) | 969 (57.3%) | 1014 (57.3%) | |
| Non-GCB | 32 (41.6%) | 721 (42.6%) | 753 (42.6%) | |
| Unknown/not done | 68 | 920 | 988 | |
| Double hit lymphoma | <.001† | |||
| Known DHL | 23 (27.4%) | 165 (10.3%) | 188 (11.1%) | |
| Non-DHL | 61 (72.6%) | 1439 (89.7%) | 1500 (88.9%) | |
| Not done/missing | 61 | 1006 | 1067 | |
| Double Expressor | <.001† | |||
| Known positive | 25 (43.1%) | 337 (25.0%) | 362 (25.8%) | |
| Negative | 33 (56.9%) | 1009 (75.0%) | 1042 (74.2%) | |
| Not done/missing | 87 | 1264 | 1351 |
| Variable . | PPD (N =145) . | All non-PPD (N = 2610) . | Total (N = 2755) . | P value . |
|---|---|---|---|---|
| n (%) . | n (%) . | n (%) . | ||
| Age at diagnosis, y | .610∗ | |||
| Median (range) | 62.5 (19-88) | 63.0 (18-99) | 63.0 (18-99) | |
| Sex | .026† | |||
| F | 50 (34.7%) | 1153 (44.2%) | 1203 (43.7%) | |
| M | 94 (65.3%) | 1456 (55.8%) | 1550 (56.3%) | |
| Race | .892† | |||
| White | 127 (88.2%) | 2217 (85.0%) | 2344 (85.1%) | |
| Black or African American | 10 (6.9%) | 192 (7.4%) | 202 (7.3%) | |
| Unknown/not reported | 4 (2.8%) | 101 (3.9%) | 105 (3.8%) | |
| Asian | 3 (2.1%) | 74 (2.8%) | 77 (2.8%) | |
| >1 race | 0 (0.0%) | 17 (0.7%) | 17 (0.6%) | |
| American Indian/Alaska Native | 0 (0.0%) | 4 (0.2%) | 4 (0.1%) | |
| Native Hawaiian/Pacific Islander | 0 (0.0%) | 4 (0.2%) | 4 (0.1%) | |
| Ethnicity | .764† | |||
| Hispanic/Latinx | 15 (10.4%) | 325 (12.5%) | 340 (12.4%) | |
| Not Hispanic or Latinx | 126 (87.5%) | 2227 (85.4%) | 2353 (85.5%) | |
| Unknown/Not reported | 3 (2.1%) | 57 (2.2%) | 60 (2.2%) | |
| Diagnosis time interval (days) | <.001† | |||
| ≤ 14 | 68 (49.6%) | 755 (30.4%) | 823 (31.4%) | |
| > 14 | 69 (50.4%) | 1731 (69.6%) | 1800 (68.6%) | |
| Missing | 8 | 124 | 132 | |
| ECOG PS | .053† | |||
| <2 | 104 (77.0%) | 2040 (83.4%) | 2144 (83.1%) | |
| ≥2 | 31 (23.0%) | 405 (16.6%) | 436 (16.9%) | |
| Missing | 10 | 165 | 175 | |
| LDH | <.001† | |||
| ≤Normal | 27 (23.7%) | 1038 (45.2%) | 1065 (44.2%) | |
| >Normal | 87 (76.3%) | 1256 (54.8%) | 1343 (55.8%) | |
| Missing | 31 | 316 | 347 | |
| Extranodal sites | .009† | |||
| ≤1 | 92 (64.8%) | 1905 (74.7%) | 1997 (74.2%) | |
| >1 | 50 (35.2%) | 646 (25.3%) | 696 (25.8%) | |
| Missing | 3 | 59 | 62 | |
| Ann Arbor stage | <.001† | |||
| I-II | 26 (19.5%) | 950 (38.5%) | 976 (37.5%) | |
| III-IV | 107 (80.5%) | 1520 (61.5%) | 1627 (62.5%) | |
| Missing | 12 | 140 | 152 | |
| IPI group | .003† | |||
| 0-1, low | 37 (25.7%) | 956 (36.6%) | 993 (36.1%) | |
| 2, low intermediate | 35 (24.3%) | 735 (28.2%) | 770 (28.0%) | |
| 3, high intermediate | 42 (29.2%) | 574 (22.0%) | 616 (22.4%) | |
| 4-5, high | 30 (20.8%) | 344 (13.2%) | 374 (13.6%) | |
| Missing | 1 | 1 | 2 | |
| Cell of origin | .285† | |||
| Known GCB | 45 (58.4%) | 969 (57.3%) | 1014 (57.3%) | |
| Non-GCB | 32 (41.6%) | 721 (42.6%) | 753 (42.6%) | |
| Unknown/not done | 68 | 920 | 988 | |
| Double hit lymphoma | <.001† | |||
| Known DHL | 23 (27.4%) | 165 (10.3%) | 188 (11.1%) | |
| Non-DHL | 61 (72.6%) | 1439 (89.7%) | 1500 (88.9%) | |
| Not done/missing | 61 | 1006 | 1067 | |
| Double Expressor | <.001† | |||
| Known positive | 25 (43.1%) | 337 (25.0%) | 362 (25.8%) | |
| Negative | 33 (56.9%) | 1009 (75.0%) | 1042 (74.2%) | |
| Not done/missing | 87 | 1264 | 1351 |
Double-hit defined as MYC rearrangement with BCL2 and/or BCL6; double expressor defined as expression of MYC and BCL2.
DHL, double hit lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; F, females; GCB, germinal center B cell; LDH, lactate dehydrogenase; M, male; non-GCB, activated B-cell subtype.
Kruskal-Wallis P value.
χ2P value.